SEC 13F Intelligence

Managers / Q4 2021 · view latest →

Consonance Capital Management LP

CIK 0001544773 · 1370 AVENUE OF THE AMERICAS, SUITE 3301, NEW YORK, NY, 10019 · 212.660-8062

Reported Value
$153M
Q4 2021
Positions
15
Filings on Record
15
2019–present window
Filed
Feb 14, 2022
original filing

Summary

Consonance Capital Management LP reported $153M in U.S.-listed holdings across 15 positions for Q4 2021.

The portfolio is heavily concentrated: TNDM alone accounts for 29.5% of reported value.

Compared with Q3 2021, the fund opened 1 new position and exited 3.

Portfolio Metrics

Turnover
+25.1%
vs prior filed quarter
Top-10 Concentration
+97.7%
share of reported value
Largest Position
+29.5%
Tandem Diabetes Care
New / Exited
1 / 3
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q1 ’19: $1.6BQ1 ’19Q2 ’19: $1.4BQ3 ’19: $1.0BQ3 ’19Q4 ’19: $1.6BQ1 ’20: $1.3BQ1 ’20Q2 ’20: $1.7BQ3 ’20: $821MQ3 ’20Q4 ’20: $1.1BQ1 ’21: $938MQ1 ’21Q2 ’21: $831MQ3 ’21: $183MQ3 ’21Q4 ’21: $153MQ1 ’22: $59MQ1 ’22Q2 ’22: $24MQ3 ’22: $7MQ3 ’22filingsflow.com

Portfolio Composition

By security type
Common Stock: 62.8%Other: 24.5%ADR: 11.8%Equity WRT: 0.9%
  • Common Stock · 62.8% · $96M
  • Other · 24.5% · $38M
  • ADR · 11.8% · $18M
  • Equity WRT · 0.9% · $1M

Quarter-over-Quarter Changes full breakdown →

vs Q3 2021 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
CMPXCOMPASS THERAPEUTICS INCNEW+3.50M3.50M+$11M$11M
SLNSILENCE THERAPEUTICS PLCADDED+579.5K758.3K+$14M$18M
SURROZEN INCADDED+2.50M3.50M+$16M$22M
SRZNWSURROZEN INCADDED+832.5K1.17M+$970,000$1M
SPRINGWORKS THERAPEUTICS INCSOLD OUT−306.0K0−$19M$0
OLINK HLDG ABSOLD OUT−115.4K0−$3M$0
CASI PHARMACEUTICALS INCSOLD OUT−1.56M0−$2M$0
UTHRUNITED THERAPEUTICS CORP DELTRIMMED−98.0K59.8K−$16M$13M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q4 2021

13 positions (from 15 filing rows — )
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1TNDMTANDEM DIABETES CARE INChistory →COM NEW29.52%$45M300.7K
2GMEDGLOBUS MED INChistory →CL A17.58%$27M373.3K
3SRZNWSURROZEN INCCOM · *W EXP 08/01/20315.45%$24M4.66M
4SLNSILENCE THERAPEUTICS PLChistory →ADS11.82%$18M758.3K
5UTHRUNITED THERAPEUTICS CORP DELhistory →COM8.43%$13M59.8K
6CMPXCOMPASS THERAPEUTICS INChistory →COM7.28%$11M3.50M
7MEDICUS SCIENCES ACQUISITIONCL A SHS · *W EXP 02/12/2021.92%$3M333.3K
8JIYA ACQUISITION CORPCOM CL A1.91%$3M300.0K
9RESEARCH ALLIANCE CORP IICOM CL A1.91%$3M300.0K
10ARYA SCIENCES ACQUISITN CORPCLASS A ORD SHS1.90%$3M300.0K
11PANACEA ACQUISITION CORP IICL A SHS1.27%$2M200.0K
12HELIX ACQUISITION CORPCOM CL A0.97%$1M150.0K
13CAREMAX INC*W EXP 06/08/2020.04%$64,00046.0K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q3 2022$7M2Nov 14, 202213F-HRchanges · EDGAR ↗
Q2 2022$24M7Aug 15, 202213F-HRchanges · EDGAR ↗
Q1 2022$59M8May 16, 202213F-HRchanges · EDGAR ↗
Q4 2021$153M15Feb 14, 202213F-HRchanges · EDGAR ↗
Q3 2021$183M17Nov 15, 202113F-HRchanges · EDGAR ↗
Q2 2021$831M32Aug 16, 202113F-HRchanges · EDGAR ↗
Q1 2021$938M35May 17, 202113F-HRchanges · EDGAR ↗
Q4 2020$1.1B38Feb 16, 202113F-HRchanges · EDGAR ↗
Q3 2020$821M27Nov 16, 202013F-HRchanges · EDGAR ↗
Q2 2020$1.7B32Aug 14, 202013F-HRchanges · EDGAR ↗
Q1 2020$1.3B31May 15, 202013F-HRchanges · EDGAR ↗
Q4 2019$1.6B35Feb 14, 202013F-HRchanges · EDGAR ↗
Q3 2019$1.0B30Nov 14, 201913F-HRchanges · EDGAR ↗
Q2 2019$1.4B30Aug 14, 201913F-HRchanges · EDGAR ↗
Q1 2019$1.6B26May 15, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.